Home | | Clinical Cases in Anesthesia | What is the treatment of supraventricular tachydys-rhythmias?

Chapter: Clinical Cases in Anesthesia : Cardiopulmonary Resuscitation

What is the treatment of supraventricular tachydys-rhythmias?

The most important initial step is to evaluate whether the patient with an underlying tachycardia is stable or unstable.

What is the treatment of supraventricular tachydys-rhythmias?

 

The most important initial step is to evaluate whether the patient with an underlying tachycardia is stable or unstable. Tachycardias in unstable patients require imme-diate electrical cardioversion, whereas stable tachycardias are usually treated with drugs and/or electric cardioversion until further evaluation and diagnostic measures can be performed. It is extremely important to treat all wide com-plex tachydysrhythmias as VT. Clinical or ECG criteria used to differentiate wide complex supraventricular tachy-cardias from VT are problematic. Administration of verapamil to a patient with VT may cause irreversible hemo-dynamic collapse. However, since adenosine has almost no effect on blood pressure, it can be tried in stable patients who are suspected of having a wide complex supraventric-ular tachycardia. Adenosine is an endogenous purine nucleoside that depresses sinus and AV nodal activity that is extremely short-acting (the serum half-life is less than 5 seconds) and produces few significant side-effects.

 

In narrow complex supraventricular tachycardias, vagal maneuvers should be performed or adenosine (0.1 mg/kg i.v. push) administered to help identify the exact underlying rhythm. Treatment also depends on the underlying cardiac function (preserved or impaired, ejection fraction (EF) <40%, congestive heart failure). Paroxysmal supraventricular tachy-cardias can be treated with calcium-channel blockers, β-blockers, digoxin, or amiodarone (the latter especially in the patient with impaired cardiac function). In junctional tachycardia or ectopic or multifocal atrial tachycardia, elec-trical cardioversion is not recommended.

 

If atrial fibrillation/flutter is suspected as the underlying rhythm, it is imperative to evaluate the patient before further management is initiated. If possible, the patient’s cardiac function should be assessed, a Wolff-Parkinson-White (WPW) syndrome ruled out, and the time of onset of atrial fibrillation determined (<48 hours or >48 hours). The goals are to treat unstable patients urgently to control the rate, convert the rhythm, and to provide anticoagulation. Patients with an onset of symptoms > 48 hours should be evaluated for thrombi in the atria using transesophageal echocardiography (TEE) before electric cardioversion is attempted. WPW patients are preferably treated with elec-tric cardioversion or amiodarone. In these patients, adeno-sine, β-blockers, calcium-channel blockers, and digoxin are contraindicated. These drugs can lead to an increased ven-tricular response or may precipitate VF by selectively blocking the AV node in patients with coexisting accessory conduction pathways. Once the diagnosis of atrial fibrilla-tion/flutter is confirmed, treatment usually consists of elec-tric cardioversion, β-blockers, calcium-channel blockers (e.g., diltiazem), or digoxin. Amiodarone is preferred in the unstable patient or the patient with impaired ventricular function (Table 1.1).

 


 






Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Clinical Cases in Anesthesia : Cardiopulmonary Resuscitation : What is the treatment of supraventricular tachydys-rhythmias? |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.